• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC TO-T/A filed by Generation Bio Co.

    1/12/26 7:58:22 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBIO alert in real time by email
    SC TO-T/A 1 d56037dsctota.htm SC TO-T/A SC TO-T/A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE TO

    (Amendment No. 1)

    TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

     

    GENERATION BIO CO.

    (Name of Subject Company (Issuer))

     

     

    XRA 7 CORP.

    (Name of Filing Persons (Co-Offeror))

    XOMA ROYALTY CORPORATION

    (Name of Filing Persons (Co-Offeror))

     

     

    Common Stock, Par Value $0.0001 Per Share

    (Title of Class of Securities)

    37148K209

    (CUSIP Number of Class of Securities)

    Owen Hughes

    XOMA Royalty Corporation

    2200 Powell Street, Suite 310

    Emeryville, California 94608

    Tel. (510) 204-7200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

     

     

    Copies to:

    Ryan A. Murr

    Branden C. Berns

    Gibson, Dunn & Crutcher LLP

    One Embarcadero Center, Suite 2600

    San Francisco, CA 94111

     

     

    ☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

    Check the appropriate boxes below to designate any transactions to which the statement relates:

    ☒ third-party tender offer subject to Rule 14d-1.

    ☐ issuer tender offer subject to Rule 13e-4.

    ☐ going-private transaction subject to Rule 13e-3.

    ☐ amendment to Schedule 13D under Rule 13d-2.

    Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

    If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

    ☐  Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

    ☐  Rule 13d-1(d) (Cross-Border Third-Party Tender Offer)

     

     
     


    AMENDMENT NO. 1

    TO

    TENDER OFFER

    This Amendment No. 1 to Tender Offer Statement on Schedule TO (this “Amendment”) relates to the offer (the “Offer”) by XOMA Royalty Corporation, a Nevada corporation (“Parent”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub” and together with Parent, “Buyer Entities”), to acquire all of the issued and outstanding shares (the “Company Shares”) of common stock, par value $0.0001 per share (the “Company Common Stock”), of Generation Bio Co., a Delaware corporation (the “Company”), for (i) $4.2913 per Company Share, payable in cash, without interest and less any applicable tax withholding (such amount, or any different amount per share paid pursuant to the Offer, the “Cash Amount”), plus (ii) one non-tradable contingent value right per Company Share (each, a “CVR”), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of the CVR Agreement (as defined in the Offer to Purchase) (the Cash Amount plus one CVR, together, the “Offer Price”), all upon the terms and subject to the conditions described in the Offer to Purchase, dated January 9, 2026 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the related Letter of Transmittal, copies of which were included as exhibits to the original Schedule TO-T filed in connection with the Offer.

    This Amendment is being filed to amend the date on which the Offer will expire from one minute after 11:59 p.m. Eastern Time on February 8, 2026 to one minute after 11:59 p.m. Eastern Time on February 6, 2026 (the “Expiration Date”). This Amendment does not amend or modify any other terms of the Offer set forth in the Offer to Purchase or in the other Offer materials originally mailed to the Company’s stockholders, except for the Expiration Date.

    The information in the Offer to Purchase, including all schedules and annexes thereto, is hereby expressly incorporated herein by reference in response to all the items of this Amendment.


    SIGNATURE

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: January 12, 2026

     

    XRA 7 Corp.
    By:   /s/ Owen Hughes
      Name: Owen Hughes
      Title: President, Treasurer and Secretary
    XOMA Royalty Corporation
    By:   /s/ Owen Hughes
      Name: Owen Hughes
      Title: Chief Executive Officer
    Get the next $GBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GBIO

    DatePrice TargetRatingAnalyst
    12/16/2025$5.50Neutral → Outperform
    Wedbush
    12/16/2025$5.00Buy → Hold
    Jefferies
    8/13/2025$7.00Outperform → Neutral
    Wedbush
    10/19/2023Outperform → Market Perform
    TD Cowen
    11/8/2022$9.00Buy
    Canaccord Genuity
    12/15/2021$40.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$50.00 → $27.00Buy
    Needham
    12/14/2021Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $GBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Generation Bio upgraded by Wedbush with a new price target

    Wedbush upgraded Generation Bio from Neutral to Outperform and set a new price target of $5.50

    12/16/25 12:29:16 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by Jefferies with a new price target

    Jefferies downgraded Generation Bio from Buy to Hold and set a new price target of $5.00

    12/16/25 8:41:52 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Generation Bio from Outperform to Neutral and set a new price target of $7.00

    8/13/25 8:02:22 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NodThera Appoints Geoff McDonough, M.D., as Independent Board Member

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced the appointment of Geoff McDonough, M.D., as an Independent Board Member. Dr. McDonough brings more than two decades of leadership experience spanning R&D, commercial strategy, and global company building. He most recently served as President and Chief Executive Officer of Generation Bio (NASDAQ:GBIO). Dr. McDonough previously served as President and CEO of Sobi, overseeing substantial portfolio expansion and international growth. Earlier in his career, Dr. McDonough spen

    12/16/25 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Enters into Agreement to Acquire Generation Bio

    - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty's portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders

    12/15/25 5:00:00 PM ET
    $GBIO
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Announces Third Quarter 2025 Financial Results

    CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results Cash Position: Cash, cash equivalents, and marketable securities were $89.6 million as of September 30, 2025, compared to $185.2 million as of December 31, 2024. The company expects that its cash, cash equivalents, and marketable securities will fund its operating expenditures for the foreseeable future.R&D Expenses: Research and development (R&D) expenses were $21.7 million for the quarter ended September 30, 2025, compared to $15.1 million for the quarter ended September 30, 2024.G&A Expenses:

    11/5/25 4:05:00 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcdonough Geoff converted options into 659 shares and covered exercise/tax liability with 293 shares, increasing direct ownership by 0.27% to 137,202 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    11/21/25 5:00:11 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Samayoa Phillip

    4 - Generation Bio Co. (0001733294) (Issuer)

    10/31/25 4:05:08 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF OPERATING OFFICER Paone Antoinette

    4 - Generation Bio Co. (0001733294) (Issuer)

    10/31/25 4:05:05 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    SEC Filings

    View All

    Amendment: SEC Form SC TO-T/A filed by Generation Bio Co.

    SC TO-T/A - Generation Bio Co. (0001733294) (Subject)

    1/12/26 7:58:22 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 14D9 filed by Generation Bio Co.

    SC 14D9 - Generation Bio Co. (0001733294) (Subject)

    1/9/26 4:49:46 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC TO-T filed by Generation Bio Co.

    SC TO-T - Generation Bio Co. (0001733294) (Subject)

    1/9/26 4:05:36 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    1/14/25 4:05:17 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    12/11/23 4:30:19 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

    4 - Generation Bio Co. (0001733294) (Issuer)

    12/6/23 4:30:13 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    12/9/24 6:18:02 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    11/14/24 1:22:38 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    2/14/24 10:03:03 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Appoints Geoff McDonough, M.D., as Independent Board Member

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced the appointment of Geoff McDonough, M.D., as an Independent Board Member. Dr. McDonough brings more than two decades of leadership experience spanning R&D, commercial strategy, and global company building. He most recently served as President and Chief Executive Officer of Generation Bio (NASDAQ:GBIO). Dr. McDonough previously served as President and CEO of Sobi, overseeing substantial portfolio expansion and international growth. Earlier in his career, Dr. McDonough spen

    12/16/25 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio Announces CEO Transition

    • Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company's Board of Directors. The Board has appointed Yalonda Howze, JD, as Interim Chief Executive Officer and President. Ms. Howze has served as the Company's Chief Legal Officer since joini

    10/22/25 4:05:00 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

    Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

    2/6/25 5:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GBIO
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty Enters into Agreement to Acquire Generation Bio

    - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty's portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders

    12/15/25 5:00:00 PM ET
    $GBIO
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care